Literature DB >> 20353175

Biochemical and structural characterization of Mycobacterium tuberculosis beta-lactamase with the carbapenems ertapenem and doripenem.

Lee W Tremblay1, Fan Fan, John S Blanchard.   

Abstract

Despite the enormous success of beta-lactams as broad-spectrum antibacterials, they have never been widely used for the treatment of tuberculosis (TB) due to intrinsic resistance that is caused by the presence of a chromosomally encoded gene (blaC) in Mycobacterium tuberculosis. Our previous studies of TB BlaC revealed that this enzyme is an extremely broad-spectrum beta-lactamase hydrolyzing all beta-lactam classes. Carbapenems are slow substrates that acylate the enzyme but are only slowly deacylated and can therefore act also as potent inhibitors of BlaC. We conducted the in vitro characterization of doripenem and ertapenem with BlaC. A steady-state kinetic burst was observed with both compounds with magnitudes proportional to the concentration of BlaC used. The results provide apparent K(m) and k(cat) values of 0.18 microM and 0.016 min(-1) for doripenem and 0.18 microM and 0.017 min(-1) for ertapenem, respectively. FTICR mass spectrometry demonstrated that the doripenem and ertapenem acyl-enzyme complexes remain stable over a time period of 90 min. The BlaC-doripenem covalent complex obtained after a 90 min soak was determined to 2.2 A, while the BlaC-ertapenem complex obtained after a 90 min soak was determined to 2.0 A. The 1.3 A diffraction data from a 10 min ertapenem-soaked crystal revealed an isomerization occurring in the BlaC-ertapenem adduct in which the original Delta(2)-pyrroline ring was tautomerized to generate the Delta(1)-pyrroline ring. The isomerization leads to the flipping of the carbapenem hydroxyethyl group to hydrogen bond to carboxyl O2 of Glu166. The hydroxyethyl flip results in both the decreased basicity of Glu166 and a significant increase in the distance between carboxyl O2 of Glu166 and the catalytic water molecule, slowing hydrolysis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20353175      PMCID: PMC2860635          DOI: 10.1021/bi100232q

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  23 in total

1.  Use of pharmacokinetic-pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem.

Authors:  Sujata M Bhavnani; Jeffrey P Hammel; Brenda B Cirincione; Matthew A Wikler; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

2.  Emergence of resistance to imipenem in Pseudomonas aeruginosa.

Authors:  M J Lynch; G L Drusano; H L Mobley
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

3.  Inhibition of the RTEM beta-lactamase from Escherichia coli. Interaction of the enzyme with derivatives of olivanic acid.

Authors:  C J Easton; J R Knowles
Journal:  Biochemistry       Date:  1982-06-08       Impact factor: 3.162

4.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1.

Authors:  Michiyosi Nukaga; Christopher R Bethel; Jodi M Thomson; Andrea M Hujer; Anne Distler; Vernon E Anderson; James R Knox; Robert A Bonomo
Journal:  J Am Chem Soc       Date:  2008-08-30       Impact factor: 15.419

Review 5.  Doripenem: a new carbapenem in the treatment of nosocomial infection.

Authors:  Lionel Mandell
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

6.  Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.

Authors:  Lee W Tremblay; Jean-Emmanuel Hugonnet; John S Blanchard
Journal:  Biochemistry       Date:  2008-04-19       Impact factor: 3.162

7.  Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin.

Authors:  J Birnbaum; F M Kahan; H Kropp; J S MacDonald
Journal:  Am J Med       Date:  1985-06-07       Impact factor: 4.965

8.  Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin.

Authors:  G Calandra; E Lydick; J Carrigan; L Weiss; H Guess
Journal:  Am J Med       Date:  1988-05       Impact factor: 4.965

9.  Carbapenems and SHV-1 beta-lactamase form different acyl-enzyme populations in crystals and solution.

Authors:  Matthew Kalp; Paul R Carey
Journal:  Biochemistry       Date:  2008-10-16       Impact factor: 3.162

10.  Ertapenem susceptibility of extended spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care centre in India.

Authors:  B Behera; P Mathur; A Das; A Kapil
Journal:  Singapore Med J       Date:  2009-06       Impact factor: 1.858

View more
  46 in total

1.  Structures of the Michaelis complex (1.2 Å) and the covalent acyl intermediate (2.0 Å) of cefamandole bound in the active sites of the Mycobacterium tuberculosis β-lactamase K73A and E166A mutants.

Authors:  Lee W Tremblay; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2010-10-25       Impact factor: 3.162

Review 2.  Antibiotic resistance mechanisms in M. tuberculosis: an update.

Authors:  Liem Nguyen
Journal:  Arch Toxicol       Date:  2016-05-09       Impact factor: 5.153

3.  A Tyrosine Residue Along with a Glutamic Acid of the Omega-Like Loop Governs the Beta-Lactamase Activity of MSMEG_4455 in Mycobacterium smegmatis.

Authors:  Ankita Bansal; Debasish Kar; Satya Deo Pandey; Ashok Matcha; N Ganesh Kumar; Soshina Nathan; Anindya S Ghosh
Journal:  Protein J       Date:  2017-06       Impact factor: 2.371

4.  Withdrawn

Authors: 
Journal:  Infect Disord Drug Targets       Date:  2012-11-16

5.  Carbapenems and Rifampin Exhibit Synergy against Mycobacterium tuberculosis and Mycobacterium abscessus.

Authors:  Amit Kaushik; Nayani Makkar; Pooja Pandey; Nicole Parrish; Urvashi Singh; Gyanu Lamichhane
Journal:  Antimicrob Agents Chemother       Date:  2015-08-10       Impact factor: 5.191

6.  Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis.

Authors:  Carmen Chow; Hua Xu; John S Blanchard
Journal:  Biochemistry       Date:  2013-05-30       Impact factor: 3.162

7.  A kinetic analysis of the inhibition of FOX-4 β-lactamase, a plasmid-mediated AmpC cephalosporinase, by monocyclic β-lactams and carbapenems.

Authors:  Krisztina M Papp-Wallace; Susana Mallo; Christopher R Bethel; Magdalena A Taracila; Andrea M Hujer; Ana Fernández; Julian A Gatta; Kerri M Smith; Yan Xu; Malcolm G P Page; Eric Desarbre; Germán Bou; Robert A Bonomo
Journal:  J Antimicrob Chemother       Date:  2013-11-13       Impact factor: 5.790

8.  Involvement of efflux pumps in the resistance to peptidoglycan synthesis inhibitors in Mycobacterium tuberculosis.

Authors:  Neela Dinesh; Sreevalli Sharma; Meenakshi Balganesh
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

9.  The binding of antibiotics in OmpF porin.

Authors:  Brigitte K Ziervogel; Benoît Roux
Journal:  Structure       Date:  2012-11-29       Impact factor: 5.006

10.  Rapid point-of-care detection of the tuberculosis pathogen using a BlaC-specific fluorogenic probe.

Authors:  Hexin Xie; Joseph Mire; Ying Kong; MiHee Chang; Hany A Hassounah; Chris N Thornton; James C Sacchettini; Jeffrey D Cirillo; Jianghong Rao
Journal:  Nat Chem       Date:  2012-09-02       Impact factor: 24.427

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.